Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707634 | 0.95 | LMNA (0.57) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL4081817 | 0.81 | HCAR2 (0.56) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL11555754 | 0.79 | CKS1B (0.60) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL16707641 | 0.79 | HCAR2 (0.72) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL21987068 | 0.78 | MEN1 (0.72) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL252026 | 0.77 | HPGD (0.79) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL7129676 | 0.77 | HPGD (0.79) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL1940746 | 0.76 | CYP3A4 (0.54) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL21987008 | 0.76 | MEN1 (1.00) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL16707625 | 0.75 | MAPT (0.74) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | claimed |
| EP-2331523-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2011-06-15 | — | — | EP | claimed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | claimed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | MEN1 4411/4885KMT2A 3159/4885MAPT 2373/4885 |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | MEN1 4411/4885KMT2A 3159/4885MAPT 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.